resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
12. März 2020 07:30 ET
|
resTORbio, Inc.
BOSTON, March 12, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
20. Februar 2020 08:00 ET
|
resTORbio, Inc.
BOSTON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
19. Februar 2020 08:00 ET
|
resTORbio, Inc.
-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in...
resTORbio to Present at Upcoming Investor Conferences
26. November 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
15. November 2019 07:00 ET
|
resTORbio, Inc.
-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- --...
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
05. November 2019 07:00 ET
|
resTORbio, Inc.
Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek™ 2019 BOSTON, Nov. 05,...
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
02. Oktober 2019 06:00 ET
|
resTORbio, Inc.
BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
25. September 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
23. September 2019 08:09 ET
|
resTORbio, Inc.
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update
14. August 2019 07:31 ET
|
resTORbio, Inc.
– Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug. 14, 2019 (GLOBE...